Scientist Awarded AHA Grant to Develop Therapies for Rare Form of Childhood Muscular Dystrophy
Dr. Bijan K. Dey in his research laboratory at The RNA Institute (Photo by Mark Schmidt).
|
ALBANY, N.Y. (Aug. 7, 2017) – Scientist Bijan K. Dey could soon offer hope to young patients with a rare form of muscular dystrophy.
Dey, a faculty researcher at The RNA Institute at the University at Albany, has received the American Heart Association’s (AHA) prestigious Scientist Development Grant to develop therapies for a deadly genetic childhood-muscle degenerative disease known as Duchenne Muscular Dystrophy (DMD).
DMD is a hereditary condition characterized by progressive muscle weaknesses and muscle degeneration. Among the nine types of muscular dystrophy, DMD is the most severe and life-threatening. It is caused by an absence of dystrophin, a protein that helps keep muscle cells intact. As the disease progresses, it weakens the heart and respiratory muscles causing serious medical issues.
Symptoms typically begin in early childhood, usually between the ages of 3 and 5. Children with DMD are commonly restricted to wheelchairs within the first decade of their lives with an average life expectancy of 26. It primarily affects young boys.
“My team is exploring a novel approach for therapy that has not been previously investigated,” Dey said. “Our goal is to gain a better understanding of the pathophysiology of DMD and DMD-associated heart dysfunctions in molecular detail. We are thankful for the American Heart Association’s support.”
Dey’s research is focused on a class of small non-coding RNA molecules called microRNAs. During his postdoctoral training at the University of Virginia School of Medicine, he demonstrated that small non-coding RNA molecules regulate the stem cell population crucial to maintaining normal skeletal and cardiac muscle function – or normal human health.
Dey works with his laboratory scientist and students (Photo by Mark Schmidt).
|
His lab is investigating how microRNAs maintain normal muscle function and what goes wrong when children are diagnosed with DMD and associated heart dysfunctions.
“Dey’s innovative research program speaks to the vision of The RNA Institute to create translational therapies requiring both basic and applied research on non-coding RNA’s role in muscle development and related human diseases,” said Paul Agris, founding director of The RNA Institute and professor of biology at UAlbany. “Dr. Dey has the knowledge and experience to bring a whole new approach to muscular dystrophy research and take it to a new height.”
Marlene Belfort, a distinguished professor at UAlbany and interim director of The RNA Institute, added that Dey has demonstrated his knowledge and expertise by earning highly competitive funding on the national stage. “At this funding climate, it is extremely challenging for a young investigator to be awarded an extramural grant early in their career,” she said.
Dey’s project is funded by the AHA through June 2020 for $231,000. It will not only support his research but also allow for mentor-based training of students and future scientists through The RNA Institute.
Students are encouraged to email Dey if interested in research opportunities in his lab: [email protected]
For more news, subscribe to UAlbany's RSS headline feeds
A comprehensive public research university, the University at Albany-SUNY offers more than 120 undergraduate majors and minors and 125 master's, doctoral and graduate certificate programs. UAlbany is a leader among all New York State colleges and universities in such diverse fields as atmospheric and environmental sciences, business, education, public health,health sciences, criminal justice, emergency preparedness, engineering and applied sciences, informatics, public administration, social welfare and sociology, taught by an extensive roster of faculty experts. It also offers expanded academic and research opportunities for students through an affiliation with Albany Law School. With a curriculum enhanced by 600 study-abroad opportunities, UAlbany launches great careers.